Neuropathy with leflunomide reported to ADRAC
- PDF / 123,101 Bytes
- 1 Pages / 623.591 x 841.847 pts Page_size
- 89 Downloads / 188 Views
1
Neuropathy with leflunomide reported to ADRAC To date, there have been 659 reports in association with leflunomide received by ADRAC, and 30 of these described neuropathy or peripheral neuropathy. In 24 of these cases, leflunomide was the sole suspected drug. According to ADRAC, most reports described an insidious onset of bilateral sensory changes such as hypoaesthesia, paraesthesia, numbness, or painful burning sensations in the hands and feet. Furthermore, symptoms persisted and worsened with continued leflunomide use in several cases. ADRAC says that patients’ ages ranged from 33–90 years, the time to onset (n = 21) was 2 weeks to 20 months, and the leflunomide daily dosage was 20mg in 24 cases, 30mg in one case, 10mg in one case, and not stated in the rest of the cases. Six patients recovered after leflunomide withdrawal; three of these patients received colestyramine ‘washout’. Fifteen patients had not recovered at the time of reporting; patient outcomes were not known for the remaining patients. According to ADRAC, these cases of neuropathy with leflunomide are similar to those reported in a previous case series.* ADRAC says "the temporal association of leflunomide with peripheral neuropathy and recovery on dechallenge suggest a causal relationship". * See Reactions 1051 p12–13; 801007156 Adverse Drug Reactions Advisory Committee (ADRAC). Leflunomide and peripheral neuropathy. Australian Adverse Drug Reactions Bulletin 25: 18-19, No. 801013699 5, Oct 2006
0114-9954/10/1123-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 14 Oct 2006 No. 1123
Data Loading...
